New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Patients could have four more years of good health on the new drug while trial users have seen cognitive improvements too ...

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, “real-world” data from people with mild Alzheimer's disease shows.

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Both lecanemab and aducanumab (marketed as Aduhelm), which the FDA approved in 2021, are monoclonal antibodies—laboratory manufactured proteins—designed to target and remove the beta amyloid ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...

A new Alzheimer’s drug, lecanemab, may slow disease progression and offer patients up to four extra years of stable health.

Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.